Decheng Capital LLC Purchases 63,200 Shares of Arcellx, Inc. (NASDAQ:ACLX)

Decheng Capital LLC raised its holdings in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 298.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 84,377 shares of the company's stock after buying an additional 63,200 shares during the quarter. Arcellx accounts for about 1.4% of Decheng Capital LLC's investment portfolio, making the stock its 15th largest position. Decheng Capital LLC owned about 0.16% of Arcellx worth $6,471,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ACLX. Headlands Technologies LLC acquired a new stake in Arcellx in the 4th quarter valued at approximately $41,000. KBC Group NV grew its holdings in shares of Arcellx by 37.3% during the 4th quarter. KBC Group NV now owns 1,388 shares of the company's stock worth $106,000 after purchasing an additional 377 shares in the last quarter. Avanza Fonder AB acquired a new stake in shares of Arcellx during the 4th quarter worth approximately $184,000. Kazazian Asset Management LLC acquired a new stake in shares of Arcellx during the 4th quarter worth approximately $204,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of Arcellx during the 4th quarter worth approximately $214,000. Institutional investors and hedge funds own 96.03% of the company's stock.

Arcellx Stock Performance

Shares of NASDAQ:ACLX traded down $0.18 during trading on Thursday, hitting $64.77. 125,571 shares of the stock were exchanged, compared to its average volume of 648,241. Arcellx, Inc. has a 1-year low of $47.88 and a 1-year high of $107.37. The company has a market capitalization of $3.57 billion, a price-to-earnings ratio of -91.23 and a beta of 0.33. The company's fifty day simple moving average is $64.77 and its 200-day simple moving average is $74.43.

Arcellx (NASDAQ:ACLX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.24). The firm had revenue of $15.27 million for the quarter, compared to analyst estimates of $27.42 million. Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. On average, research analysts forecast that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

Insider Activity at Arcellx

In other Arcellx news, Director Kavita Patel sold 1,500 shares of Arcellx stock in a transaction on Tuesday, April 8th. The stock was sold at an average price of $57.50, for a total value of $86,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Christopher Heery sold 10,155 shares of Arcellx stock in a transaction on Monday, February 24th. The shares were sold at an average price of $63.79, for a total value of $647,787.45. Following the completion of the transaction, the insider now owns 37,486 shares of the company's stock, valued at approximately $2,391,231.94. The trade was a 21.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,955 shares of company stock valued at $3,504,758 in the last 90 days. 6.24% of the stock is owned by corporate insiders.

Arcellx Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).